Oruka Therapeutics
ORKA
25 hedge funds and large institutions have $12.7M invested in Oruka Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
94% more capital invested
Capital invested by funds: $6.55M → $12.7M (+$6.16M)
19% more funds holding
Funds holding: 21 → 25 (+4)
2.44% more ownership
Funds ownership: 1.88% → 4.32% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$441K |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$60.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$22.7K |
| 4 |
Renaissance Technologies
New York
|
+$12.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$94.4K |
| 2 |
NM
Newtyn Management
New York
|
-$57.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.26K |
| 4 |
BlackRock
New York
|
-$90 |
ORKA Hedge Fund Activity: Q4 2023 in Review
25 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2023, worth a combined $12.7M — up 94% from $6.55M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ORKA positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Western Standard LLC, adding an estimated $441K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $94.4K sold.
- 25 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $12.7M of Oruka Therapeutics stock for Q4 2023, up 94% quarter-over-quarter.
- 5 funds opened new Oruka Therapeutics positions in Q4 2023 and 1 closed out, a net change of +4 holders.
- The largest Oruka Therapeutics buyer in Q4 2023 was Western Standard LLC, an estimated $441K added.
- The largest Oruka Therapeutics seller in Q4 2023 was Bridgeway Capital Management, an estimated $94.4K sold.
Based on aggregated 13F filings for Q4 2023.